Does Recurrent Pancreatic Cancer Really Have Similar Outcome Compared With Primary Metastatic Pancreatic Cancer?

Completed

• Conditions: Pancreatic Cancer Metastatic
• Interventions: Drug: chemotherapy agents

• Registration Number: NCT06921252
• Lead Sponsor: Kochi University

Brief Summary

The recurrent pancreatic cancer (Rec-PC) after radical surgery is sometimes eligible to clinical trial of chemotherapy for unresectable pancreatic cancer. However, the difference between Rec-PC and primary metastatic pancreatic cancer (PM-PC) did not know well. Thus, whether Rec-PC and PM-PC should be included in the same category when conducting clinical trials evaluating chemotherapy remains controversial. The purpose of this study is to investigate the difference of overall survival (OS) between Rec-PC and PM-PC, and analyze their impact on prognosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01-01
• Primary Completion: 2025-03-01
• Study Completion: 2025-03-01
• Study First Submitted: 2025-03-13
• Status Verified: 2025-04
• Study First Submitted QC: 2025-04-03
• Last Update Submitted: 2025-04-03
• Study First Posted: 2025-04-10
• Last Update Posted: 2025-04-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 276

Inclusion Criteria

• unresectable pancreatic cancer

Exclusion Criteria

• Patients expected to survive for less than three months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
chemotherapy for metastatic pancreatic cancer	chemotherapy agents	chemotherapy
chemotherapy for recurrent pancreatic cancer	chemotherapy agents	postoperative chemotherapy

Primary Outcome Measures

Name	Time	Method
Overall survival	From date of evaluation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months